• Prescribing Information
  • Patient Information
  • Patient Site
  • Medical Information
  • Vyndamax logo

    Access & Patient Support

    Patient access and reimbursement

    Financial assistance options

    Additional support during treatment

    When you've decided VYNDAMAX is appropriate for your patient, VyndaLink can help

    Enroll your patients in VyndaLink for support

    The VyndaLink team can:​​​​​​​

    Conduct a benefits verification to determine your patient's coverage for VYNDAMAX and VYNDAQEL® (tafamidis meglumine), including out-of-pocket costs

    Determine payer requirements and provide information about the prior authorization process and appeals process as needed*

    Identify Specialty Pharmacy options based on your patient’s insurance coverage. VYNDAMAX is available through multiple Specialty Pharmacies in our defined distribution network

      *Please note where a PA is required, the physician must submit required information directly to the patient's insurer.​​​

    Get started at www.VyndaLink.com

    Download the enrollment form. Completed form can be sent online at www.VyndaLinkPortal.com or faxed to
    ​​​​​​​1-888-878-8474. Call 1-888-222-8475 (Monday-Friday, 8 AM-8 PM ET) with any questions.

    Visit VyndaLink


    By using this co-pay card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:

    • Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
    • Patient must have private insurance. Offer is not valid for cash-paying patients. Patients are responsible for as little as a $0 monthly co-payment based upon program utilization. The value of this co-pay card is limited to a maximum of $60,000 per calendar year.
    • This co-pay card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
    • You must deduct the value of this co-pay card from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
    • You are responsible for reporting use of the co-pay card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer co-pay cards.
    • You must be 18 years of age or older to redeem the co-pay card.
    • This co-pay card is not valid where prohibited by law.
    • Co-pay card cannot be combined with any other savings, free trial, or similar offer for the specified prescription.
    • Co-pay card will be accepted only at participating pharmacies.
    • This co-pay card is not health insurance.
    • Offer good only in the U.S. and Puerto Rico.
    • Co-pay card is limited to 1 per person during this offering period and is not transferable.
    • A co-pay card may be redeemed for either a VYNDAMAX or VYNDAQEL prescription, but not more than once per 24 days per patient.
    • No other purchase is necessary.
    • No membership fee.
    • Data related to your redemption of the co-pay card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you.
    • Pfizer reserves the right to rescind, revoke or amend this offer without notice.
    • Offer expires 12/31/2021.
    ​​​​​​​For more information, visit our website www.VyndaLink.com,
    call 1-888-222-8475, or write:
    Pfizer Attn: Claims Processing Department, IQVIA, Inc. 77 Corporate Drive, Bridgewater, NJ 08807

    Next: Financial assistance options


    Savings & Support

    • Access & Patient Support
    • Resources
    View Support & Services

    VyndaLink.com has more information about support services for you and your patients

    View VyndaLink

    Access resources for you and your patient

    Explore resources

    VYNDAMAX® AND VYNDAQEL® are registered trademarks of Pfizer Inc.

    Adverse Reactions

    In studies in patients with ATTR-CM, the frequency of adverse events in patients treated with VYNDAQEL® (tafamidis meglumine) was similar to placebo.

    Specific Populations

    Pregnancy: Based on findings from animal studies, VYNDAQEL and VYNDAMAX may cause fetal harm when administered to a pregnant woman.

    Lactation: There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk. When a drug is present in animal milk, it is likely the drug will be present in human milk. Breastfeeding is not recommended during treatment with VYNDAQEL and VYNDAMAX.

    VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
    Please see Full Prescribing Information including Patient Information.


      VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.
      Please see Full Prescribing Information including Patient Information.